Jeffrey Brown talks with health correspondent Susan Dentzer and Dr. John Reveille, director of the Division of Rheumatology at the University of Texas Health Science Center in Houston, about the ...

NEW YORK (AP) - Pfizer Inc. said Friday its pain reliever Celebrex showed no increased overall risk of cardiovascular problems in a massive analysis of 41 completed studies involving 44,000 patients.

New research suggests that top-selling pain reliever Celebrex does not carry the same heart attack risk as Vioxx, a similar drug pulled from the market in September because of safety concerns.

NEW ORLEANS (Reuters) - Pfizer Inc's Celebrex arthritis drug was shown to be at least as safe as the widely used prescription-strength versions of painkillers ibuprofen and naproxen, and does not ...

Pfizer's decision to continue selling the arthritis medication Celebrex -- which, based on the results of a national study announced on Friday, can triple patient risk for cardiovascular events ...

Pfizer says a study found an increased risk of heart problems with the painkiller Celebrex. The news comes after another painkiller, Vioxx, was withdrawn from the market. Like Vioxx, Celebrex is in a ...